Navigation Links
Risperdal Lawsuits Progress, as Bernstein Liebhard LLP Notes Filing of Plaintiff Brief Seeking to Unseal Risperdal Clinical Studies

New York, New York (PRWEB) December 12, 2013

Risperdal lawsuits ( , including many that allege use of the antipsychotic drug caused some men and young boys to develop gynecomastia, or male breast growth, continue to move forward in a consolidated litigation underway in the Philadelphia Court of Common Pleas in Pennsylvania. According to a brief filed earlier this month, Plaintiffs have asked the court to reject a request from Johnson & Johnson to allow some Risperdal clinical studies to remain sealed. Among other things, Plaintiffs assert that the risks allegedly associated with Risperdal are too great to keep the documents from the public. (In Re: Risperdal Litigation, Case Number 100300296)

According to court records, the documents in question were originally sealed by the Court in 2011. In November, Johnson & Johnson filed a motion with the Court asking that the Risperdal studies remain sealed, asserting that they were intended to be used by researchers and regulators, and were never meant to be circulated to the general public.

“Our Firm has heard from numerous patients concerned about the potential link between Risperdal and gynecomastia. We will be monitoring this issue very closely, and look forward to the Court’s decision,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently evaluating Risperdal lawsuits on behalf of men and boys who may developed gynecomastia allegedly due to their use of the drug.

Risperdal Lawsuits
Court documents indicate that 275 lawsuits, including many that allege a connection between the use of Risperdal and gynecomastia, are pending in the Pennsylvania litigation. All of the complaints accuse Johnson & Johnson of concealing serious Risperdal side effects, including male breast growth. The lawsuits also allege that the drug was improperly marketed for off-label uses, including for use in children.

The U.S. Department of Justice announced on November 4th that it had reached a settlement with Johnson & Johnson regarding the improper marketing of Risperdal and other drugs. According to a statement issued by federal prosecutors, the $2.2 billion accord was one of the largest health care settlements in history. Among other things, the Justice Department had alleged that Risperdal was illegally marketed for use in children prior to the approval of pediatric uses in 2006. The government had also alleged that side effects associated with the drug were concealed, including an association between Risperdal and male breast growth. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Men and young boys who developed gynecomastia while taking Risperdal may be entitled to compensation for their injury related damages. To learn more about the potential association between Risperdal and male breast growth, please visit Bernstein Liebhard LLP’s website. For a free Risperdal lawsuit review, please call 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Parker Waichman LLP Commends Arkansas Attorney General for Backing Fine Against Johnson & Johnson over Risperdal Off-Label Marketing Allegations
2. The Consumer Justice Foundation Launches, an Informational Web Site Dealing with Alleged Risperdal Side Effects Including Gynecomastia
3. Bernstein Liebhard LLP Investigating Risperdal Lawsuits on Behalf of Victims of Male Breast Growth Allegedly Caused by Risperdal
4. New Risperdal Lawsuit Filed in Pennsylvania Litigation; Alleges Male Breast Growth Injuries Caused by Anti-Psychotic Medication, Bernstein Liebhard LLP Reports
5. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Settlement in Risperdal Marketing Investigation
6. Risperdal Lawsuits: $2.2 Billion Settlement Between Federal Government, Johnson & Johnson Over Alleged Illegal Marketing of Risperdal, Other Medications
7. Risperdal Lawsuit News: Johnson & Johnson To Pay Over $2.2 Billion In Risperdal and Invega Settlement Draws Comment From Wright & Schulte LLC
8. J&J to Pay $2.2B to Settle Allegations Over Its Marketing of Risperdal; Parker Waichman LLP Applauds Efforts of Whistleblowers in Helping Compel Resolution
9. Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on $2 Billion Risperdal Settlement Report
10. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Mounting Claims Involving Risperdal Gynecomastia Allegations in Pennsylvania Litigation
11. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Release of Emails from Johnson & Johnson’s Janssen Subsidiary in Federal Risperdal Settlement
Post Your Comments:
(Date:12/1/2015)... ... December 02, 2015 , ... ... events and association with initiation of treatment for osteoporosis ”. , As corresponding ... pharmacological treatment in patients diagnosed with osteoporosis. Based on a large US managed ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an article published ... discrimination claim against the U.S. Department of Health and Human Services, claiming that any ... plans are breaking the clause in the law prohibiting the denial of coverage for ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of ... has been named by MedEsthetics magazine as the Best Single Physician Practice in the ... the many elite aesthetic physicians honored by the industry publication. , Dr. Vitenas ...
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... in the 1980s we have seen vast improvements in scientific research and discoveries, ... significant strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic ... United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a ... catastrophic contributors to diseases of the diabetic foot. The American Board of ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Dec. 1, 2015 Array BioPharma ... that its Chief Executive Officer, Ron ... Annual Healthcare Conference in New York.  The ... conference through a webcast on the Array ... , --> , ...
(Date:12/1/2015)... Dec. 1, 2015 Assurex Health, Inc. ... test giving healthcare providers an expanded range of ... patients suffering from depression, anxiety, bipolar disorder, posttraumatic ... conditions. i .   ... With the addition of two new drug classes, ...
(Date:12/1/2015)... 1, 2015 --> ... report "Nucleic Acid Labeling Market by Product (Reagents & ... Primer, In Vitro Transcription, Reverse Transcription, End Labeling), by ... The global market is expected to reach USD 1,925.7 ... growing at a CAGR of 8.65%. Browse ...
Breaking Medicine Technology: